Breaking News

CMLE Passes PAI for API

By Gil Roth | September 19, 2011

Weert facility approved after two-day inspection

Cambridge Major Laboratories Europe (CMLE), a supplier of chemistry services supporting drug substance development, has successfully completed its first regulatory pre-approval inspection (PAI) for a commercial API. The audit of its Weert facilities was conducted over a two-day period from on Aug. 31 and Sept. 1. At the same time, the site's general certificate to manufacture drug substance intended for clinical trial application was renewed for another three years.
“This is a major step forward for CML Europe” commented general director Peter van Tilburg. “We have consistently invested in staff, procedures and facilities over the last 10 years, and this approval demonstrates our commitment to the highest quality standards. It is a result of all the hard work undertaken by every single team member, and our common vision for the future of CML.”
“We are already recognized as a development powerhouse,” added Roger McDonald, European business development director for CMLE. “This approval demonstrates our ability to provide top-quality services to clients at all development phases, from candidate nomination right through to commercial launch. Considering the recent announcement of successful FDA inspection at our new Grant Drive facility in the U.S., we feel this is a great testament to the quality CML Corporate is committed to meet. We want to be the long-term partner of choice for clients.”

Related Contract Manufacturing:

Related Compliance:

  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars

  • Continuous Pharmaceutical Processes and Their Demands

    Continuous Pharmaceutical Processes and Their Demands

    Girish Malhotra, EPCOT International||April 5, 2016
    A look at the unique characteristics of continuous processes in pharmaceutical manufacturing.